Abstract:Emerging evidence suggests the critical roles of N6-methyladenosine (m6A) RNA modification in tumorigenesis and tumor progression. However, the role of m6A in non-small cell lung cancer (NSCLC) is still unclear. This study aimed to explore the role of the m6A demethylase fat mass and obesity-associated protein (FTO) in the tumor metastasis of NSCLC. A human m6A epitranscriptomic microarray analysis was used to identify downstream targets of FTO. Quantitative real-time PCR (qRT‒PCR) and western blotting were employed to evaluate the expression levels of FTO and FAP in NSCLC cell lines and tissues. Gain-of-function and loss-of-function assays were conducted in vivo and in vitro to assess the effects of FTO and FAP on NSCLC metastasis. M6A-RNA immunoprecipitation (MeRIP), RNA immunoprecipitation (RIP), luciferase reporter assays, and RNA stability assays were used to explore the mechanism of FTO action. Co-immunoprecipitation (co-IP) assays were used to determine the mechanism of FAP in NSCLC metastasis. FTO was upregulated and predicted poor prognosis in patients with NSCLC. FTO promoted cell migration and invasion in NSCLC, and the FAK inhibitor defactinib (VS6063) suppressed NSCLC metastasis induced by overexpression of FTO. Mechanistically, FTO facilitated NSCLC metastasis by modifying the m6A level of FAP in a YTHDF2-dependent manner. Moreover, FTO-mediated metastasis formation depended on the interactions between FAP and integrin family members, which further activated the FAK signaling. Our current findings provided valuable insights into the role of FTO-mediated m6A demethylation modification in NSCLC metastasis. FTO was identified as a contributor to NSCLC metastasis through the activation of the FAP/integrin/FAK signaling, which may be a potential therapeutic target for NSCLC. Emerging evidence suggests the crucial roles of N6-methyladenosine (m6A) RNA modification in tumorigenesis and progression. Nonetheless, the role of m6A in NSCLC remains unclear. The purpose of this study was to investigate the role of m6A demethylase fat mass and obesity-associated protein (FTO) in the tumor metastasis of non-small cell lung cancer (NSCLC). Results illustrated that FTO was upregulated and predicted poor prognosis in NSCLC patients. FTO promoted cell migration and invasion in NSCLC, and the FAK inhibitor defactinib (VS6063) suppressed NSCLC metastasis induced by overexpression of FTO. Mechanistically, FTO facilitated NSCLC metastasis by modifying the m6A level of FAP in a YTHDF2-dependent manner. Moreover, FTO-mediated metastasis formation depended on the interactions between FAP and integrin family members, which further activated the FAK signaling. Our current findings provided valuable insights into the role of FTO-mediated m6A demethylation modification in NSCLC metastasis. FTO was identified as a contributor to NSCLC metastasis through the activation of the FAP/integrin/FAK signaling, which may be a potential therapeutic target for NSCLC.

FTO-Mediated Downregulation of RAMP2-AS1 Promotes Glycolysis in Non-Small Cell Lung Cancer Cells by Inhibiting KLF9-Mediated Transcriptional Activation of LATS2

FOXP3 Targets KIF5A to Increase Lactate Production and Promote Docetaxel Resistance in Lung Adenocarcinoma

HIF1A-dependent Overexpression of MTFP1 Promotes Lung Squamous Cell Carcinoma Development by Activating the Glycolysis Pathway

LncRNA GAS5 regulated by FTO-mediated m6A demethylation promotes autophagic cell death in NSCLC by targeting UPF1/BRD4 axis

Long Noncoding RNA AGPG Regulates PFKFB3-mediated Tumor Glycolytic Reprogramming

FTO Facilitates Cancer Metastasis by Modifying the M 6 A Level of FAP to Induce Integrin/fak Signaling in Non-Small Cell Lung Cancer

FTO Facilitates Lung Adenocarcinoma Cell Progression by Activating Cell Migration Through Mrna Demethylation

METTL3-induced DLGAP1-AS2 promotes non-small cell lung cancer tumorigenesis through m6A/c-Myc-dependent aerobic glycolysis

Down-regulated FTO and ALKBH5 co-operatively activates FOXO signaling through m6A methylation modification in HK2 mRNA mediated by IGF2BP2 to enhance glycolysis in colorectal cancer

Down-regulation of LATS2 in Non-Small Cell Lung Cancer Promoted the Growth and Motility of Cancer Cells

WNT/-catenin-suppressed FTO expression increases m<SUP>6</SUP>A of c-Myc mRNA to promote tumor cell glycolysis and tumorigenesis

m6A demethylase FTO induces NELL2 expression by inhibiting E2F1 m6A modification leading to metastasis of non-small cell lung cancer

Frequent Inactivation of RAMP2, EFEMP1 and Dutt1 in Lung Cancer by Promoter Hypermethylation.

Synergistic Effects Between Mtor Complex 1/2 and Glycolysis Inhibitors on Non-Small Cell Lung Carcinoma Metabolism.

WNT/β-catenin-suppressed FTO expression increases m6A of c-Myc mRNA to promote tumor cell glycolysis and tumorigenesis

WNT/β-catenin-suppressed FTO expression increases m 6 A of c-Myc mRNA to promote tumor cell glycolysis and tumorigenesis

N6-methyladenosine Demethyltransferase FTO Mediated M6a Modification of Estrogen Receptor Alpha in Non-Small Cell Lung Cancer Tumorigenesis

FTO facilitates cancer metastasis by modifying the m6A level of FAP to induce integrin/FAK signaling in non-small cell lung cancer

The M6a Modification-Mediated OGDHL Exerts a Tumor Suppressor Role in Ccrcc by Downregulating FASN to Inhibit Lipid Synthesis and ERK Signaling.

Long Noncoding RNA SLC2A1‐AS1 Regulates Aerobic Glycolysis and Progression in Hepatocellular Carcinoma Via Inhibiting the STAT3/FOXM1/GLUT1 Pathway

N 6 -methyladenosine demethyltransferase FTO mediated m 6 A modification of estrogen receptor alpha in non-small cell lung cancer tumorigenesis